MULTI-FACTORIAL ANALYSIS OF THE INTENSITY OF EXUDATE ACCUMULATION IN THE PLEURAL CAVITY
Keywords:
The causes of PAD, ECG (if necessary, EchoCG, FVD), pulse oximetry, Ultrasound examination, Computed tomography (CT)Abstract
Treatment of malignant hydrothorax primarily consists in eliminating the accumulation of fluid in the pleural cavity, which depends on the intensity of accumulation of the latter. Not fully developed problem is the prognostic factors affecting the outcome of the disease. Until today, adequate methods of treating this pathology have not been determined. Standards for indications for medicinal, radiation and surgical methods of treatment have not been developed.The intense progression of the disease indicates the aggressiveness of the tumor process, its expansiveness. Conversely, slow development, less intense progression, indicates a relatively favorable course of the disease. The patients included in our study had a history of malignant neoplastic process from 6 months to 5 years. 162 (80.2%) patients included in the study had a short, up to one year, history of malignant tumor. In 15 (7.4%) patients, the accumulation of pleural fluid coincided with the progression of tumor growth after a year of the onset of the disease. In 25 (12.4%) patients, local control was not achieved during treatment.
References
Ault M.J., Rosen B.T., Scher J., Feinglass J., Barsuk J.H. Thoracentesis outcomes: A 12-year experience. Thorax. 2015;70:127–132.
Bray F., Ferlay J., Soerjomataram I., Siegel R.L., Torre L.A., Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2018;68:394–424.
Havelock T., Teoh R., Laws D., Gleeson F. Pleural procedures and thoracic ultrasound: British Thoracic Society pleural disease guideline 2010. Thorax. 2010;65:i61–i76.
Kindler H.L., Ismaila N., Armato S.G., Bueno R., Hesdorffer M., Jahan T., Jones C.M., Miettinen M., Pass H., Rimner A., et al. Treatment of Malignant Pleural Mesothelioma: American Society of Clinical Oncology Clinical Practice Guideline. J. Clin. Oncol. 2018;36:1343–1373.
Roberts ME, Neville E, Berristford RG, et al. Management of malignant pleural effusion: British Thoracic Society pleural disease guideline 2010. Thorax. 2010;65(Suppl 2):ii32–ii40.
Taghizadeh N, Fortin M, Tremblay A. US hospitalizations for malignant pleural effusions: data from the 2012 National Inpatient Sample. Chest 2017; 151: 845–854
U.S. National Medical Library. "Pleural Disorders." MedlinePlus. Bethesda, Maryland;
Vidmayer, Erik P. Raff, Xershel; Strang, Kevin T. (2006). Vander's Human Physiology: Mechanisms of Body Activity (10th ed.). Boston, Massachusetts: McGraw-Hill. ISBN 978-0072827415.
^ Kasha, Aaron R .; Caruana-Gauci, Roberto; Mansh, Alexander; Gausi, Marilyn; Chetketi, Stanley; Bertolachini, Luke; Skarchi, Marco (April 2017). "The theory of pleural pressure has been revised: the role of capillary balance." Journal of Chest Disease. 9 (4): 979–989. doi: 10.21037 / jtd.2017.03.112. ISSN 2072-1439. PMC 5418293. PMID 28523153.
^ Boron, Walter F .; Boulpaep, Emil L. (2015). Fisiologia medica (2). Elsevier Mosbi. ISBN 978-85-352-6851-5. OCLC 949753083.
^ Lay-Fuk, Stephen J. (April 2004). "Pleural Mechanics and Fluid Exchange." Physiological reviews. 84 (2): 385–410. doi: 10.1152 / physrev.00026.2003. ISSN 0031-9333. PMID 15044678.
